{
    "ticker": "ADTX",
    "name": "Aditx Therapeutics, Inc.",
    "description": "Aditx Therapeutics, Inc. is a biotechnology company dedicated to advancing the field of immunology through innovative therapeutic solutions. Founded in 2019 and based in San Diego, California, Aditx focuses on the discovery, development, and commercialization of proprietary immune modulation therapies designed to treat a variety of diseases, including cancer and autoimmune disorders. The company's unique approach leverages its proprietary ADiTx technology platform to identify and develop therapies that harness the immune system's potential to combat disease more effectively. Aditx is committed to addressing unmet medical needs and improving patient outcomes through its cutting-edge research and development initiatives. The company's lead product candidate, ADiTx-101, is currently in clinical trials targeting autoimmune diseases, demonstrating promising early results. Aditx Therapeutics aims to revolutionize the treatment landscape by offering safer, more effective options that utilize the body's natural defenses. With a strong pipeline of product candidates, Aditx is positioned to make significant contributions to the biotechnology sector and improve the lives of patients worldwide.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2019",
    "website": "https://www.aditx.com",
    "ceo": "David A. S. F. M. K. H. D. Choi",
    "social_media": {
        "twitter": "https://twitter.com/AditxTherapeutics",
        "linkedin": "https://www.linkedin.com/company/aditx-therapeutics"
    },
    "investor_relations": "https://ir.aditx.com",
    "key_executives": [
        {
            "name": "David A. S. F. M. K. H. D. Choi",
            "position": "CEO"
        },
        {
            "name": "Sonia A. L. F. R. K. M. R. M. M. M. Choi",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutic Candidates",
            "products": [
                "ADiTx-101"
            ]
        }
    ],
    "seo": {
        "meta_title": "Aditx Therapeutics, Inc. | Innovative Immunology Solutions",
        "meta_description": "Explore Aditx Therapeutics, Inc., a biotechnology leader focused on immune modulation therapies for cancer and autoimmune diseases.",
        "keywords": [
            "Aditx",
            "Biotechnology",
            "Immunology",
            "Cancer Treatment",
            "Autoimmune Disorders",
            "Therapeutics"
        ]
    },
    "faq": [
        {
            "question": "What does Aditx Therapeutics focus on?",
            "answer": "Aditx Therapeutics focuses on developing immune modulation therapies for various diseases, including cancer and autoimmune disorders."
        },
        {
            "question": "Who is the CEO of Aditx Therapeutics?",
            "answer": "David A. S. F. M. K. H. D. Choi is the CEO of Aditx Therapeutics, Inc."
        },
        {
            "question": "Where is Aditx Therapeutics headquartered?",
            "answer": "Aditx Therapeutics is headquartered in San Diego, California, USA."
        },
        {
            "question": "What is Aditx's lead product candidate?",
            "answer": "Aditx's lead product candidate is ADiTx-101."
        },
        {
            "question": "When was Aditx Therapeutics founded?",
            "answer": "Aditx Therapeutics was founded in 2019."
        }
    ],
    "competitors": [
        "SRNE",
        "CRMD",
        "BCRX",
        "GTHX"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "VRTX",
        "REGN"
    ]
}